[Skip to Navigation]
May 1990

Effect of Topically Administered Epidermal Growth Factor on Corneal Wound Strength

Author Affiliations

From the Departments of Ophthalmology (Drs Leibowitz, Morello, and Kupferman) and Pharmacology (Dr Kupferman), Boston (Mass) University School of Medicine; and Alcon Laboratoratories, Inc, Fort Worth, Tex (Dr Stern).

Arch Ophthalmol. 1990;108(5):734-737. doi:10.1001/archopht.1990.01070070120048

• A 9-mm perforating corneal wound was created in one eye of New Zealand albino rabbits, sutured, and treated with mouse-derived epidermal growth factor (1 mg/L), human-derived epidermal growth factor (1.0 mg/L to 100 mg/L), or buffered saline, instilled once, twice, or four times daily. Both mouse-derived epidermal growth factor and human-derived epidermal growth factor significantly increased the tensile strength of full-thickness corneal wounds after 9 days of topical therapy. For human-derived epidermal growth factor, a concentration of 10 mg/L administered twice daily produced the maximal effect. An increase in either the concentration of epidermal growth factor or its frequency of administration failed to induce a further increase in wound strength. Indeed, at a concentration of 100 mg/L, human-derived epidermal growth factor appeared to lose its ability to accelerate healing of full-thickness corneal wounds.

Add or change institution